4–6 Along with improved glycemic control in recent decades, this has led to a declining incidence and severity of diabetic retinopathy in the USA.83 In recent years genomic studies have identified potential genetic associations with DM retinopathy risk, for example the gene encoding the receptor for advanced glycation end products (RAGE, especially the 1704T allele)84 and the gene for http://www.selleckchem.com/products/AZD2281(Olaparib).html methylenetetrahydrofolate reductase (MTHFR),85 where the 677C/T polymorphism has been associated with modestly increased

risks for nephropathy and retinopathy. Investigators Inhibitors,research,lifescience,medical have recently reported use of proteomic methods to study proteins in the aqueous humor of the eye that may provide insights into the pathophysiology Inhibitors,research,lifescience,medical of DR,86 but proteomic and genomic testing for diabetic retinopathy risk are not yet useful in clinical practice. Diabetic Neuropathy Prediction and Prevention Peripheral nerve dysfunction results from metabolic as well as microvascular damage and may lead to significant pain, as well as loss of sensation predisposing to lower-extremity amputation. Autonomic neuropathies affect gastrointestinal motility and can lead to cardiac dysfunction. Risk for neuropathy rises

with duration of DM, degree of hypertension and hyperglycemia, as well as smoking.87 Vitamin D Inhibitors,research,lifescience,medical insufficiency may also be an independent predictor of developing neuropathy symptoms.68 Nevertheless, about 50% of DM patients appear resistant to these factors and do not develop neuropathy. Recent proteomic studies of patients with diabetic Inhibitors,research,lifescience,medical neuropathy have identified a number of proteins, including a fragment of the apolipoprotein C-I precursor, that associate with diabetic neuropathy.88 Metabolomic studies have identified phospholipid biomarkers that may improve discrimination between those DM patients with and without neuropathy.89 Such advances Inhibitors,research,lifescience,medical may lead to improved assessment of neuropathy risk and may enhance understanding of the pathophysiology

of diabetic neuropathy. PERSONALIZED MEDICINE AND CHRONIC MACROVASCULAR COMPLICATIONS OF DM While historically much attention was focused Tolmetin on preventing the aforementioned microvascular complications of DM, in reality the most significant area of preventable DM-related morbidity, mortality, and heath care utilization90 is arteriosclerotic narrowing in the coronary, cerebrovascular, and peripheral arterial beds. This results in the devastating manifestations of angina pectoris, acute myocardial infarction, sudden cardiac death, heart failure, stroke, intermittent claudication, and lower-extremity amputation. Risk of atherosclerotic cardiovascular disease (ASCVD) rises with fasting glucose even in the “prediabetes” range.